Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/5/2024 | $3.00 | Neutral | H.C. Wainwright | |
2/29/2024 | $12.00 → $8.00 | Neutral | B. Riley Securities | |
12/11/2023 | $2.00 | Sell | Goldman | |
11/17/2023 | $7.00 → $12.00 | Equal Weight → Overweight | CapitalOne | |
9/26/2023 | $15.50 → $4.75 | Sell | Citigroup | |
8/24/2023 | $19.00 | Underperform → Neutral | Wedbush | |
7/27/2023 | $15.00 → $4.00 | Buy → Neutral | UBS | |
7/25/2023 | Buy → Neutral | Chardan Capital Markets |
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
ZURICH, Sept. 4, 2024 /PRNewswire/ -- Amcor (NYSE:AMCR, ASX: AMC))), a global leader in developing and producing responsible packaging solutions, today announced that its Board of Directors has appointed Peter Konieczny as Chief Executive Officer (CEO). Mr. Konieczny has served as Interim CEO since April 2024. The Board also intends to nominate him as a director for election at the Company's Annual Meeting of Shareholders which is expected to be held in November 2024. Amcor Chairman, Mr. Graeme Liebelt, said, "Peter has demonstrated exceptional leadership in every role he has
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its FDA-cleared T2Candida® Panel for pediatric patients. The Company expects to immediately begin marketing and selling the T2Candida Panel under the expanded pediatric claim. The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida species directly-from-blood, in just 3-5 hours, without the need to wait days for a positive blood culture. The T2Candid
Marcus Glover will serve as a Class 1 director of the Company with a term expiring at the Company's 2027 Annual Meeting of Stockholders AMC Entertainment Holdings, Inc., (NYSE:AMC), the largest theatrical exhibitor in the United States and in the world, today announced that the Company's Board of Directors has elected Marcus Glover to the AMC Board of Directors, effective September 12, 2024. Glover will serve as a Class 1 director of the Company with a term expiring at the Company's 2027 Annual Meeting of Stockholders, and at that meeting will stand for re-election thereafter. He will serve as a Member of the Audit Committee. Glover brings to the Board extensive financial, operational an
H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00
B. Riley Securities reiterated coverage of AMC Entertainment with a rating of Neutral and set a new price target of $8.00 from $12.00 previously
Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00
GRAPEVINE, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today released financial results for the second quarter ended August 3, 2024. The Company's condensed and consolidated financial statements, including GAAP and non-GAAP results, are below. The Company's Form 10-Q and supplemental information can be found at https://investor.gamestop.com. SECOND QUARTER OVERVIEW Net sales were $0.798 billion for the second quarter, compared to $1.164 billion in the prior year's second quarter.Selling, general and administrative ("SG&A") expenses were $270.8 million, or 33.9% of net sales for the second quarter, compared to $322.5 million, or 27
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus
Revenue of $54.7 million exceeds guidance Advertising revenue per attendee reaches $0.56, surpassing 2019 levels National advertising revenue per attendee up 37% year-over-year National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member and owner of approximately 100% National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising network reaching movie audiences in the U.S., today announced its consolidated results for the fiscal second quarter ended June 27, 2024. "The second quarter of 2024 highlighted our continued strong performance across the key metrics of inventory utilization and monetization, with advertising revenue per attendee
SC 13G/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
Wedbush analyst Alicia Reese reiterates AMC Enter Hldgs (NYSE:AMC) with a Neutral and maintains $4 price target.
Investors with a lot of money to spend have taken a bearish stance on GameStop (NYSE:GME). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GME, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 uncommon options trades for GameStop. This isn't normal. The overall sentiment of these big-money traders is split between 4% bullish and 90%, bearish. Out of all of the special optio
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
8-K - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
144 - T2 Biosystems, Inc. (0001492674) (Subject)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Issuer)
3 - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Issuer)